BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Novotech CRO launches largest Oracle TMMCS in APAC

December 17, 2018 | News

Novotech will have the largest TMMCS implementation in the Asia-Pacific and is the first biotech-focused CRO in the region to go-live on Oracle's TMMCS technology in the cloud



Asia-Pacific specialist CRO Novotech announced as part of its ongoing IT infrastructure investment program that it has implemented the Oracle's Trial Management and Monitoring Cloud Service (TMMCS) to support its growth in the Asia-Pacific.

Oracle Health Sciences VP of Services, David Tuckfield said Novotech will have the largest TMMCS implementation in the Asia-Pacific and is the first biotech-focused CRO in the region to go-live on Oracle's TMMCS technology in the cloud. "We are delighted to be able to implement Novotech's vision of next generation trial management," he added.

Novotech, the recipient of the 2018 Frost & Sullivan Asia-Pacific Biotech CRO Company of the Year award for the 3rd consecutive year, has been operating in the Asia-Pacific for 22 years.

Novotech CEO Dr John Moller said Novotech has always invested heavily in the latest technology. This ensures regulatory compliance, allows integration into global studies, and gives Novotech teams and clients better data visibility to improve decision-making. "Oracle's cloud technology provides a centralized trial database enabling improved access, control and governance of clinical data. The system is highly configurable allowing us to tailor process flows and alerts to client needs, as well as ensuring effective control on deviations. Advanced functionalities like eSignatures, and tools for swift approvals and submissions help us accelerate trial implementation."

Novotech launched the migration project in partnership with Oracle Health Science Global Services in March 2018. Novotech has also invested in Oracle Argus for Medical Safety and Oracle Inform EDC. Novotech is a full service CRO with on-the-ground operationsin Australia, New Zealand, South Korea, China, Taiwan, Philippines, Hong Kong, Singapore, Malaysia, Thailand and India with 550+ full-time employees.

Novotech clinical staff numbers have grown by more than 20% in Asia over the last quarter, fueled by demand for a regional CRO with international accreditation and reputation, combined with local knowledge, partnerships and expertise. The CRO has extensive therapeutic area experience handling clinical studies with small and mid-size biotechnology companies across all phases of clinical trials – First-in-Human (FIH) studies to phase IV.

Novotech has managed around 700 projects including the APAC component of pivotal trials for multiple FDA, EMA registered products since 2001 Novotech has now signed 10 strategic collaborations with hospitals and research institutions in the Asia-

Pacific region. About Oracle TMMCS